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Residues in human leukemia inhibitory factor (hLIF)
crucial for binding to both the human LIF receptor (R)
and gp130 were identified by analysis of alanine scan-
ning mutants of hLIF in assays for both receptor bind-
ing and bioactivity. The region of hLIF most important
for binding to the hLIF-R is composed of residues from
the amino terminus of the D-helix, carboxyl terminus of
the B-helix, and C-D loop. This site forms a distinct sur-
face at the end of the four-helix bundle in the tertiary
structure of the closely related murine LIF. The two
residues of hLIF that contribute the majority of free
energy for hLIF-R binding, Phe-156 and Lys-159 are sur-
rounded by other residues which have only a moderate
impact. This arrangement of a few key residues sur-
rounded by less important ones is analogous to the func-
tional binding epitope of human growth hormone for its
receptor. A second region of hLIF that includes residues
from the carboxyl terminus of the D-helix and A-B loop
also had a weak influence on hLIF-R binding. Residues
in hLIF from both the A- and C-helices are involved in
binding the gp130 co-receptor. Abolition of the gp130
binding site in hLIF created antagonists of LIF action.
Leukemia inhibitory factor (1–3) is a secreted cytokine that
elicits pleiotropic effects on a diverse range of cell types, these
include embryonic stem cells, primordial germ cells, neurons,
adipocytes, hepatocytes, and osteoblasts (4, 5). In mice, gene
knockout experiments have demonstrated that LIF1 is essen-
tial for embryonic implantation (6, 7). In contrast to the mild
phenotype in mice lacking the LIF gene, the targeted deficiency
of the specific LIF receptor (LIF-R), results in mice that have
multiple placental, skeletal, neural, and metabolic disorders,
which cause perinatal death (8). The biological differences be-
tween these two genetic deficiencies is an outcome of the use of
the LIF-R for signal transduction by several ligands. The cyto-
kines known to bind to the LIF-R are included in a group that
share some biological properties with LIF: oncostatin M, ciliary
neurotrophic factor (CNTF), cardiotrophin (CT-1), interleu-
kin-6 (IL-6), and interleukin-11 (9–14).
The crystal structure of recombinant murine LIF (mLIF) has
been solved (15). LIF has a four a-helical bundle topology with
up-up-down-down helix orientation that has long crossover
loops between the first two and last two helices. The structure
of LIF shows greatest homology to granulocyte-colony-stimu-
lating factor (G-CSF; Ref. 16), human growth hormone (hGH;
Ref. 17) and the recently determined CNTF (18). These pro-
teins all belong to the hematopoietin cytokine family, which is
characterized by the four-helix bundle structure, but limited
sequence homology between family members (19–21). The he-
matopoietin cytokine family is divided into the short and long
chain subfamilies (21). The long chain group of which both LIF
and hGH are members is characterized by helices of approxi-
mately 25 residues, the presence of short helical regions in the
long loops, and the complete absence of b strands. The canon-
ical member of the hematopoietin cytokine family and most
characterized is hGH.
The co-crystal structure of hGH and its receptor (17), to-
gether with extensive mutagenesis studies of both the ligand
(22, 23) and receptor (24), have defined both the signaling
complex and binding surfaces of these molecules. The activated
GHR is formed by homodimerization of two identical receptor
subunits and a single hGH molecule (17, 25). hGH uses two
distinct sites to bind sequentially to the two growth hormone
receptors, first via site I and secondarily to site II. The higher
affinity GHR binding site on hGH, site I, involves residues in
the carboxyl terminus of both the A- and D-helices and the A-B
loop, whereas site II includes residues in both the A- and
C-helices. In contrast to the ligand, almost identical residues
on the GHR are used to bind both sites I and II on hGH.
Receptor homodimerization leading to signal transduction as
used by the GHR, erythropoietin R (26), and G-CSF-R (27)
represents the simplest form of receptor assembly. A more
complex form of receptor association involves heterodimeriza-
tion, although the exact stoichiometry of receptor components
has not been determined for the majority of theses complexes.
Such complexes use a specific cytokine binding receptor for
each ligand and often share a common signaling b chain among
several cytokines. This arrangement is demonstrated by inter-
leukin 3, granulocyte macrophage-colony stimulating factor
(GM-CSF), and interleukin-5 (IL-5), all of which use a common
b receptor together with a ligand-specific chain (28). Similarly,
the interleukins: 4, 7, 9, 15, and possibly 13 use the interleu-
kin-2 (IL-2) g chain together with a specific interleukin recep-
tor binding component for signal transduction (29). Heterotri-
meric receptor formation of three different subunits is utilized
for the association of the high affinity IL-2 receptor (30). The
most complicated receptor assembly so far characterized is that
of the signaling unit of the interleukin 6 receptor (IL-6-R). This
complex involves receptor heterodimerization, but forms a hex-
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americ complex, consisting of two molecules each of IL-6, IL-
6-R, and gp130 (31, 32).
LIF transduces its biological signal via transmembrane re-
ceptors, of which both low and high affinity forms have been
characterized. The low affinity species of the receptor (KD
'1029 M) is the single chain 190-kDa LIF receptor (33). Pri-
mary sequence comparison indicates that the LIF-R is part of
the hematopoietin receptor family (20, 34). The extracellular
region of the LIF-R is predicted to be composed of two hema-
topoietin domains separated by an immunoglobulin module
and three fibronectin type III repeats proximal to the mem-
brane (33). Hematopoietin cytokine binding domains have sev-
eral primary sequence elements conserved in nearly all mem-
bers of the family, including several cysteine residues and the
motif Trp-Ser-X-Trp-Ser (20). The structure of this domain has
been solved for both the prolactin receptor (35) and GHR (17),
these structures are composed of two b-barrels each consisting
of seven anti-parallel b-strands.
The high affinity signaling complex (KD '10
211 M) for LIF is
formed by the association of the LIF-R and a related member of
the hematopoietin receptor family, gp130 (36, 37). However,
like many other receptor complexes. the stoichiometry of com-
ponents in the activated complex is unknown. The gp130 re-
ceptor differs to the LIF-R in that this receptor is predicted to
have only a single hematopoietin domain (33, 38). Both LIF-R
and gp130 are involved in the high affinity receptor complex for
cytokines related in structure to LIF, these include oncostatin
M (37, 39), CT-1 (14, 40), and CNTF (41–43). The high affinity
CNTF receptor complex also requires the presence of a third
component, the CNTF receptor (44), whereas, oncostatin M
also uses an alternative receptor to the LIF-R (45). The gp130
receptor and not the LIF-R is also involved as a co-receptor and
signal transducer for the cytokines, IL-6 (46, 47) and IL-11 (48,
49). The common usage of gp130 and in some cases also LIF-R
for signal transduction by LIF, oncostatin M, CNTF, CT-1,
IL-6, and IL-11 explains their overlapping functional charac-
teristics. Both LIF-R and gp130 mediate intracellular signal
transduction via activation of cytoplasmic tyrosine kinases be-
longing to the JAK and Src families (50–52).
A clear understanding of how a particular cytokine interacts
with its receptors is a crucial requirement for both comprehen-
sion of receptor activation and also the design of specific ago-
nists and antagonists of cytokine action. Previous mutagenesis
studies of LIF have utilized the observation that both murine
and human LIF (hLIF) bind to the mLIF-R, but only hLIF will
bind to the hLIF-R with high affinity. These studies suggested
that residues in the C-D loop were important for this species
specificity (15, 53).
This study extended the previous work by evaluating the role
of individual residues of hLIF to the binding to both hLIF-R
and gp130. Human LIF mutants were analyzed both by direct
binding assays to recombinant LIF-R-Fc and gp130-Fc and also
for activity in a bioassay responsive to hLIF. Apart from re-
vealing residues of hLIF critical for binding hLIF-R and gp130,
abrogation of the gp130 binding site created antagonists of wild
type hLIF.
MATERIALS AND METHODS
Construction of Mutant Human LIF Expression Plasmids—The con-
struction of pGeX-hLIF and the characterization of the expressed LIF
has been described previously (15, 54). All mutant DNA sequences were
created by PCR overlap (55) using pGeX-hLIF and specific oligonucleo-
tides for each individual mutant, the sequence of the primers used are
available on request. The mutant hLIF sequences were cloned into the
pGeX plasmid, and the nucleotide sequence of all constructs was con-
firmed by DNA sequencing with Sequenase (Amersham).
Expression and Purification of Human LIF Mutants and Oncostatin
M—All mutants were expressed as glutathione S-transferase fusion
proteins in Escherichia coli JM109. The expression, purification, and
cleavage of mutant fusion hLIF proteins was performed as described
previously (15, 56). Purity of individual mutants was determined by
inspection of silver-stained SDS-PAGE gels run in a Pharmacia Biotech
Inc. Phast gel system. All mutants had a purity of greater than 80% by
this method. The protein concentration of each mutant protein was
determined by the Coomassie Plus Protein Assay (Pierce) and verified
by comparative SDS-PAGE analysis.
The mature form of oncostatin M (57) was a kind gift from Dr. D
Staunton; this protein was also expressed as a glutathione S-transfer-
ase fusion protein and purified as above.
Construction of Human LIF-R-Fc and gp130-Fc Receptor Expression
Plasmids—PCR was used to amplify the region coding for amino acids
2–538 of the human LIF receptor. This fragment was cloned into the
pIG plasmid (58) using a HindIII site 59 to the first ATG codon and a
BamHI site 39 to the codon for amino acid 528. Both sites were intro-
duced by the PCR primers: amino terminus, TAGAAGCTTCCACCAT-
GGATATTTACGTATGTTTGA; carboxyl terminus, ACGGATCCA-
CTTACCTGTCCCCTTTGAAGGACTGGCTTC.
The PCR primer matching the amino-terminal coding sequence also
introduced an optimized Kozak sequence (59), while the other primer
created a splice donor sequence between codon 528 and the BamHI site.
An identical approach was used to clone the human gp130 into the pIG
plasmid, except the region amplified coded for residues 1–328. The PCR
primers used were: amino terminus, TAGAAGCTTCCACCATGTT-
GACGTTGCAGACTTGGG; carboxyl terminus, ACGGATCCACTTA-
CCTGTTGCTTTAGATGGTCTATCTT.
The nucleotide sequences of both constructs were confirmed by DNA
sequencing with Sequenase (Amersham).
Expression and Purification of Human LIF-R-Fc and gp130-Fc—
Both the human LIF receptor and the gp130 receptor were expressed as
fusion proteins with the Fc region (hinge-CH2-CH3) of human IgG1.
The pIG expression plasmids were transfected by the calcium-phos-
phate technique (60) into a human epithelial kidney cell line 293T (61),
which expresses the large T antigen of SV40. After transfection of 293T
cells, the medium was changed to a serum-free medium (Ultra-Cho,
BioWhittaker), and the Fc-fusion proteins were left to accumulate in
the medium for 6 days. Receptor-Fc proteins were purified from filtered
supernatants by chromatography on protein A-Sepharose (Pharmacia).
Elution of the receptor was achieved with 0.1 M sodium citrate (pH 3.0).
The purity of the receptor-Fc proteins was assessed as greater than 90%
as determined by inspection of silver-stained SDS-PAGE gels run in a
Pharmacia Phast gel system.
Iodination of and Biotinylation of Ligands—Recombinant human
LIF produced as described above was iodinated using IODOBEADS
(Pierce) and [125I]iodine (Amersham) as recommended by the manufac-
turers. Iodinated LIF had a specific activity of 1–4 3 103 cpm/fmol and
was equally active in the bioassay as wild type hLIF. Recombinant
oncostatin M was biotinylated with biotinamidocaproateN-hydroxysuc-
cinimide ester (Sigma) following a published procedure (62).
Ligand Bioassays—All mutant hLIF proteins were tested for biolog-
ical activity on the Ba/F3-hLIF-R/hgp130 cell line, which expresses both
hLIF-R and hgp130 (15). The assay was performed exactly as described
previously (15). All assays were performed in triplicate for at least three
independent experiments. It was noted that different batches of cells
exhibited quantitative differences in their response to hLIF although
the relative potencies of hLIF and mutants were preserved. Antagonism
assays were also performed with the Ba/F3-hLIF-R/hgp130 cell line.
Briefly, the antagonists were titrated in the presence of a 50% maxi-
mum stimulation concentration of hLIF; otherwise, the cells were
treated exactly as for the standard bioassay.
Ligand Binding Assays—All binding assays were performed in Nunc
Maxisorp 96-well plates. For LIF-R-Fc binding, plates were first coated
with 100 ml of protein A (Sigma) at 1 mg/ml, blocked with PBS-1% BSA,
and then incubated with 100 ml of LIF-R-Fc also at 1 mg/ml. Initial
experiments indicated that the supernatant from 293T cells transfected
with LIF-R-Fc was equivalent to purified LIF-R-Fc; therefore, all sub-
sequent experiments used the LIF-R-Fc-containing supernatant. After
LIF-R-Fc binding, the plates were washed with PBS-0.05% Tween 20
and then used for the binding assay. Competition binding assays be-
tween 125I-hLIF and wild type hLIF or mutant hLIF were performed in
a volume of 60 ml in a buffer of RPMI (Life Technologies, Inc.), 20 mM
Hepes, pH 7.2, 25 mg/ml BSA, 2 mg/ml azide, 1 mM phenylmethylsul-
fonyl fluoride, and 1 mM EDTA overnight at 4 °C. After washing twice
with 200 ml of PBS-0.05% Tween 20, bound 125I-hLIF was released by
incubation in 80 ml of 1 M NaOH and counted in a g counter (LKB). All
LIF-R-Fc binding studies were performed in triplicate for at least two
independent experiments.
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Binding studies to gp130-Fc were performed in manner similar to
that for LIF-R-Fc. These assays differed in that for gp130-Fc competi-
tion binding, biotinylated oncostatin M was used instead of 125I-hLIF
and the bound oncostatin M was detected by incubation with a strepta-
vidin-horseradish peroxidase conjugate (Amersham). Specifically, after
washing plates with PBS- 0.05% Tween 20, the wells were rinsed with
PBS and then incubated with 100 ml of streptavidin-horseradish per-
oxidase (1/1000 dilution) in PBS-1% BSA. After again washing with
PBS, the horseradish peroxidase was detected by incubation with the
chromagen OPD (orthophenylenediamine; Dako) according to the man-
ufacturer’s instructions. Absorbance was read at 492 nm in a 96-well
plate reader (Anthos). All gp130-Fc binding studies were performed in
duplicate for at least two independent experiments.
RESULTS
Rationale for Human LIF Mutagenesis—The solvent acces-
sibility of residues in the structure of the closely related mLIF
(15; 79% sequence identity with hLIF) was used in conjunction
with previous mutagenesis data to target amino acids of hLIF
for mutagenesis. Alanine scanning mutagenesis (22) was used
to identify hLIF residues involved in LIF-R binding by mu-
tagenesis of amino acids in the D-helix, C-D loop, the carboxyl-
terminal end of the A-helix, and A-B loop of hLIF. The choice of
these locations was based on the results of previous LIF mu-
tagenesis (15, 53), and the site I hGH paradigm (22, 23). Sub-
sequently, residues in the vicinity of the B-C loop were also
selected for mutagenesis because of their proximity to Phe-156
(see below). The location of both the hGH site II (25) and also
the residues important for gp130 binding in the predicted IL-6
structure (63) were used as a guide for mutagenesis of the
putative gp130 binding site in hLIF. Instead of alanine-scan-
ning mutagenesis, both multiple alanine and also multiple
nonconservative substitutions were engineered to identify the
hLIF gp130 binding site.
Identification of the LIF-R Binding Site on Human LIF—
Mutant LIF molecules were assayed in two different systems
for binding to the LIF-R. First, the ability of LIF mutants to
inhibit 125I-hLIF binding to immobilized recombinant human
LIF-R-Fc is presented in Table I and Fig. 1. Second, the LIF
mutants were tested for their biological activity in a prolifera-
tion assay of the LIF-dependent cell line Ba/F3-LIF-R/gp130
(Table I and Fig. 2).
Two mutants exhibited dramatic reductions in the LIF-R-Fc
binding assay, hLIF F156A and hLIF K159A (Table I and Fig. 1),
the change in LIF-R-Fc affinity for these two mutants was also
paralleled by a large decrease in activity in the proliferation
assay (Table I and Fig. 2). A similar reduction in LIF-R-Fc bind-
ing was also observed for mutants hLIF F156A and hLIF K159A,
when assayed for competition binding with 125I-hLIF on 293T
cells transfected with the entire LIF-R reading frame (data not
shown). Despite the reduction in LIF-R-Fc affinity in these mu-
tants, no alteration in gp130-Fc affinity was observed (Table I
and Fig. 3), thus arguing that these mutations were specific for
LIF-R binding. Several other mutants demonstrated signifi-
cantly reduced binding to the LIF-R-Fc. These included hLIF
P51A, hLIF K153A, hLIF P106A, hLIF T150A, hLIF K158A, and
hLIF V175A (Table I). Finally, several mutants showed only
weak (2-fold) reduction in LIF-R-Fc binding. These mutants in-
cluded hLIF D57A, hLIF K58A, hLIF D66A, hLIF K102A, hLIF
D154A, hLIF K170A, and hLIF A174Q (Table I).
In general, the reduced LIF-R-Fc binding by the various
mutants was also accompanied by a decrease in activity in the
proliferation assay. However, the reduction in the LIF-R-Fc
binding was usually greater than the reduction in the prolifer-
ation assay, even though the proliferation assay was able to
detect lower LIF-R affinities. A lowered affinity for the LIF-
R-Fc did not necessarily translate into a parallel reduction in
biological activity, such as in mutant K153A. An analogous
observation has been reported for mutants of IL-5 (64).
Of the mutants with significantly reduced LIF-R-Fc binding,
all but three mutants had unchanged gp130-Fc affinity. The
three mutants with altered gp130-Fc affinity all had less than
4-fold decreases in affinity. These mutants were hLIF P106A,
hLIF K153A, and hLIF D154A (Table I). The reduced affinity
for gp130-Fc in the hLIF P106Amutant may be due to a change
in the conformation of the B-C loop and thus may affect the
packing of the C-helix, a contributor to gp130 binding (see
below). For the hLIF K153A mutant, an additional mutation
randomly introduced by PCR is present in the D-helix (G162D,
Table I), this extra change may alter the packing of the A-B
loop against the D-helix and thus disrupt the structure. The
presence of this second mutation confounds the contribution of
Lys-153 to LIF-R binding.
Overall, the residues in hLIF that contribute the majority of
free energy for binding to the LIF-R are located at the begin-
ning of the D-helix (Phe-156 and Lys-159); these residues are
spatially close together and have their side chains prominently
exposed to the solvent in the hLIF structure (Fig. 5). Other
residues that influence LIF-R binding map to the beginning of
the D-helix (Lys-158), B-helix (Lys-102), and C-D loop (Thr-
150); these amino acids are proximal to Phe-156 and Lys-159.
Residues in the A-B loop (Asp-57, Lys-58) and the carboxyl
terminus of the D-helix (Lys-170, Ala-174, Val-175) may form a
second site of interaction with the LIF-R.
Identification of the gp130 Binding Site on Human LIF—
Mutant hLIF molecules were also assayed in two different
systems for binding to the gp130 receptor. First, the relative
affinity for binding to gp130-Fc was assessed by the ability of
LIF mutants to inhibit biotinylated oncostatin M binding to
immobilized recombinant human gp130-Fc (Table I and Fig. 3).
Oncostatin M binds gp130-Fc with a significantly higher affin-
ity than LIF and thus provides a convenient tracer for this type
of binding assay. Second, the LIF mutants were also examined
in the Ba/F3-LIF-R/gp130 proliferation assay (Table I and Fig.
2). All mutants with alterations in the beginning of both the
A-helix and C-helix exhibited undetectable gp130-Fc binding
and varied from a 250-fold reduction to undetectable stimula-
tion in the bioassay (Table I and Figs. 2 and 3). In contrast to
the gp130-Fc binding, the A- and C-helix mutants showed a
similar affinity to wild-type LIF in the LIF-R-Fc binding assay
(Table I and Fig. 1). The results from the bioassay using mu-
tants with multiple alanine substitutions in the A- or the
C-helix (hLIF-O4 and hLIF-O2) strongly suggest that residues
in both the A- and C-helices of hLIF contribute to binding the
gp130 receptor (Fig. 2). The greater reduction in bioactivity
seen in the hLIF-O4 mutant compared to the hLIF-O2 mutant
(Fig. 2B) indicates that, for LIF, the majority of binding energy
for gp130 resides in the A-helix residues. Identification of the
individual contribution of each hLIF residue to gp130 binding
will require further mutagenesis of hLIF.
Antagonist Activity of Human LIF Mutants Impaired in
gp130 Binding—LIF mutants shown to have large decreases in
gp130-Fc binding were assayed for their ability to antagonize
hLIF stimulation of the cell line Ba/F3-hLIF-R/hgp130. The
results presented in Fig. 4 demonstrate that several of these
mutants show antagonistic activity. In this assay, the inhibi-
tion was specific to hLIF since murine IL-3 stimulation of the
Ba/F3-hLIF-R/hgp130 cell line was unaffected by the various
antagonists (data not shown). Only mutants with the greatest
reduction in the proliferation assay showed antagonism activ-
ity (hLIF-O1, -O3, -O4, and -O5; Table I and Fig. 4). Mutants
with significant residual proliferation in the bioassay such as
hLIF-O2 and -O6 exhibited no antagonistic characteristics (Ta-
ble I and Fig. 4). Of the four mutants that exhibited antago-
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nism of hLIF-dependent Ba/F3-hLIF-R/hgp130 stimulation,
the mutant hLIF-O4 was clearly the most effective (Fig. 4).
DISCUSSION
Activation of hematopoietin receptors requires at least the
dimerization of two transmembrane receptors with cytoplasmic
domains capable of signal transduction. The role of the ligand
is to facilitate the oligomerization process. In the simplest
example, signal transduction results from receptor homodimer-
ization like the classical GHR. A more complex interaction
involves receptor activation through heterodimerization; the
activated human LIF receptor belongs in this category.
This study has identified residues of hLIF crucial for binding
to both the LIF-R and gp130 by analysis of hLIF mutants in
solid phase binding studies to both the LIF-R-Fc and gp130-Fc
and also a bioassay responsive to LIF. The detectable binding of
two different receptors to hLIF provided a convenient control
for protein folding in mutant molecules. Thus, mutants that
had decreased binding in one receptor but not the other
strongly supported the idea that individual mutations caused
local rather than global changes in structure.
The hLIF residues Lys-159 and Phe-156 provide the majority
of free energy for binding to the LIF-R. These two residues are
located at the beginning of the D-helix, with their side chains
adjacent and prominently exposed to the solvent in both the
mLIF molecule and the recently determined hLIF structure
(Fig. 5).2 Surrounding Lys-159 and Phe-156 are several other
residues in close proximity that influence the binding of hLIF
to the hLIF-R (Table I); collectively, these amino acids form a
2 R. C. Robinson et al., submitted for publication.
TABLE I
Summary of receptor binding and LIF bioassay data for LIF mutants
Data represents the mean values of the various experiments.
wild type or hLIF
mutant
Location of mutation on
hLIF structurea
Ratio LIF-R binding:
IC50
b mutant/IC50 hLif
Ratio gp130 binding:
IC50 mutant/IC50 hLif
Ratio Baf stimulation:
EC50
c mutant/EC50 hLif
hLIF 1 1 1
Y45A A-helix 1.0 1.0 1.0
T46A A-helix 0.8 1.0 0.5
E50A A-B loop 1.0 0.75 1.0
P51A A-B loop 8.0 1.0 5.0
P53A A-B loop 1.1 0.9 1.6
N54A A-B loop 1.0 1.0 0.8
N55A A-B loop 1.0 1.0 1.0
D57A A-B loop 2.2 1.2 1.1
K58A A-B loop 2.0 0.8 2.0
G61A A-B loop 1.5 1.0 1.0
P62A A-B loop 1.8 1.0 1.5
N63A A-B loop 1.0 1.0 1.0
V64A A-B loop 1.0 1.3 1.0
T65A A-B loop 1.0 1.0 1.0
D66A A-B loop 2.0 0.8 1.0
K102A B-helix 2.0 1.0 2.0
I103A B-helix 0.5 1.0 1.0
P106A B-C loop 4.0 3.3 2.0
S107A B-C loop 1.0 0.9 0.8
D149A C-D loop 1.6 1.0 1.0
T150A C-D loop 4.0 1.0 1.2
S151A C-D loop 1.6 0.4 1.0
G152A C-D loop 1.0 1.0 1.0
K153Ad C-D loop 45 3.0 4.0
D154A C-D loop 2.0 2.5 2.0
V155A D-helix 1.0 0.7 1.0
F156A D-helix .100 1.1 700
Q157A D-helix 0.8 1.0 1.0
K158A D-helix 3.0 1.0 1.0
K159A D-helix .100 1.0 3,000
K168A D-helix 1.0 1.0 1.0
K170A D-helix 2.0 0.7 1.1
Q171A D-helix 1.4 1.0 1.5
A174Q D-helix 2.0 0.9 2.0
V175A D-helix 3.0 1.1 1.1
A177Q D-helix 1.0 1.0 2.0
Q178A D-helix 1.0 1.0 1.0
hLIF-O1e A- and C-helix 1.0 .10 .100,000
hLIF-O2f C-helix 1.0 .10 250
hLIF-O3g A-helix 1.8 .10 .100,000
hLIF-O4h A-helix 1.2 .10 .100,000
hLIF-O5i A- and C-helix 2.0 .10 .100,000
hLIF-06j A- C-helix 1.0 .10 .1,000
Oncostatin-M .100 0.01 10
a Residues were assigned structural types according to the designations in the crystal structure of mLIF (15).
b IC50 refers to the concentration of mutant or wild type protein required to inhibit 50% of the binding of the labeled species.
c EC50 refers to the concentration of mutant or wild type protein required to activate the LIF bioassay by 50% of maximum stimulation.
d The mutant hLIF-K153A has the additional mutation G162D introduced randomly by PCR.
e Mutations in hLIF-O1: Q25A, S28A, A117E, D120R, I121K, G124N, S127L.
f Mutations in hLIF-O2: D120A, I121A, G124A, S127A.
g Mutations in hLIF-O3: Q25L, S28E, Q32A, S36K.
h Mutations in hLIF-O4: Q25A, S28A, Q32A.
i Mutations in hLIF-O5: A117E, D120R, I121K, G124N, S127L, Q25L, S28E, Q32A, S36K.
j Mutations in hLIF-O6: Q25A, S28A, S36A, D120A, I121A, G124A, S127A.
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distinct region at the end of the four-helix bundle in the terti-
ary structure of hLIF (Fig. 5). The arrangement of the LIF-R
binding site of hLIF into a few pivotal residues surrounded by
ones of lesser importance was also observed in the interaction
of the hGH site I with the GHR (23).
The C-D loop and surrounding residues of hLIF have been
identified previously by chimera studies as being responsible
for the difference in binding affinity of murine and hLIF to the
hLIF-R (15, 53, 65). In the most refined form of this analysis,
six mLIF residues were mutated to the equivalent hLIF resi-
dues (E57D, T107S, Q112H, V113S, A155V, and R158K; Ref.
65) to give the mutated mLIF molecule high affinity binding to
the hLIF-R. That these residues were not identified in this
investigation as significant contributors of hLIF binding to
hLIF-R may suggest these residues prevent mLIF binding to
the hLIF-R with high affinity by either structural or chemical
interference. This hypothesis is supported by the observation
that the human and mLIF structures show no major shifts in
the peptide backbone in the vicinity important for LIF-R
binding.2
Other cytokines related to hLIF in primary sequence: mLIF,
oncostatin M, CNTF, and CT-1 that can involve the hLIF-R in
the activated receptor complex all have the hLIF residues
Phe-156 and Lys-159 conserved (15, 40), whereas IL-6 and
IL-11 which do not bind the LIF-R lack these residues. No other
residues of hLIF that influence binding to the LIF-R are con-
served in all of these hLIF-R binding ligands. Thus, the equiv-
alents of hLIF Phe-156 and Lys-159 in these other ligands may
represent a common LIF-R binding motif. However, like mLIF,
all of these molecules (excluding CT-1, which has yet to be
examined) bind hLIF-R with significantly lower affinity than
hLIF (15, 39, 41, 43, 53, 66). Therefore, a LIF-R binding epitope
involving homologues of Phe-156 and Lys-159 must be modu-
lated by other residues in each individual cytokine.
The majority of hLIF residues identified in this study that
were important for hLIF-R binding cluster at the end of the
four-helix bundle. However, five residues with a weak influence
FIG. 1. Competitive inhibition of 125I-hLIF (0.165 nM) binding
to LIF-R-Fc by hLIF or hLIF mutants. Results are expressed as a
ratio of counts bound at a particular concentration of competitor [B]
divided by counts bound in the absence of competitor [B0]. Values
represent the mean of triplicate samples, the S.E. for all points was less
than 10% of the mean. A: M, hLIF; E, hLIF F156A; , hLIF K159A. B:
M, hLIF;, hLIF-O1;L, hLIF-O3;E, hLIF-O5. C: M, hLIF;, hLIF-O2;
L, hLIF-O4; E, hLIF-O6.
FIG. 2. Biological activity of hLIF or hLIF mutants in the Ba/
F3-hLIF-R/hgp130 assay. Results are expressed as the A570 value of
cells assayed for proliferation by 3-(4,5-dimethyl thiazol-2-yl)-2,5-di-
phenyl tetrazolium bromide (79). Values represent the mean of tripli-
cate samples, the S.E. for all points was less than 10% of the mean. A:
M, hLIF; E, hLIF F156A; L, hLIF K159A; , oncostatin M. B: M, hLIF;
E, hLIF-O1; , hLIF-O2; L, hLIF-O3; *, hLIF-O4; Q, hLIF-O5; µ,
hLIF-O6.
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on hLIF-R binding map to the carboxyl-terminal end of the
D-helix and the A-B loop (Asp-57, Lys-58, Lys-170, Ala-174,
Val-175). These residues may represent a second site of contact
between hLIF and the hLIF-R. This second site could represent
interaction with either another LIF-R molecule or another part
of the LIF-R. Both these possibilities would be compatible with
the use of a similar site on other long chain hematopoietin
cytokines (see below and Table II). The latter possibility is also
in accordance with models proposed for LIF binding based on
both the predicted two-hematopoietin domain structure of the
LIF-R and competition binding characteristics of murine and
hLIF (15, 67). In these models, one LIF molecule is able to bind
simultaneously to two distinct sites on a single LIF-R. How-
ever, the existence of a second site on LIF for LIF-R binding site
requires further verification.
Residues of hLIF important for binding to gp130 were iden-
tified in a manner analogous to those involved in the LIF-R
binding site, except that multiple simultaneous substitutions
were used to locate the gp130 binding site. The interaction of
LIF with gp130 is significantly weaker than the interaction
with LIF-R which limits the ability to detect the influence of
individual mutations with weak effects on the interaction with
gp130. This analysis indicated that residues at the amino ter-
minus of the A-helix contributed the majority of free energy for
binding to gp130. In particular, all or a subset of the A-helix
residues Gln-25, Ser-28, and Gln-32, participate directly in
gp130 binding. The mutation of the C-helix residues: Asp-120,
Ile-121, Gly-124, and Ser-127 also reduced gp130 binding, sug-
gesting that all or some of these residues also interact with
gp130. However, the role of individual hLIF amino acids in
binding to gp130 cannot be determined for either the A- or
C-helices without further mutagenesis investigations.
Antagonists for several different four-helical bundle cyto-
kines have been created previously by mutations in ligand
receptor binding surfaces. These engineered antagonists in-
clude those for ligands which homodimerize their receptors, for
FIG. 3. Competitive inhibition of biotinylated oncostatin M
(0.8 nM) binding to gp130-Fc by hLIF or hLIFmutants. Results are
expressed as a ratio of biotinylated oncostatin M bound att a particular
concentration of competitor [B] divided by biotinylated oncostatin M
bound in the absence of competitor [B0]. Values represent the mean of
duplicate samples. A: M, hLIF; L, hLIF F156A; E, hLIF K159A; ,
oncostatin M. B: M, LIF; , hLIF-O1; L, hLIF-O3; E, hLIF-O5. C: M,
hLIF; , hLIF-O2; L, hLIF-O4; E, hLIF-O6.
FIG. 4. Antagonism of hLIF stimulation of the Ba/F3-hLIF-R/
hgp130 cell line by hLIF mutants impaired in gp130 binding.
Human LIF mutants were titrated in the presence of a constant con-
centration of hLIF (0.015 nM). Results are expressed as the A570 value
of cells assayed for proliferation by 3-(4,5-dimethyl thiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (79). Values represent the mean of trip-
licate samples, the S.E. for all points was less than 10% of the mean. A:
M, no antagonist; E, hLIF-O1; a, hLIF-O3; , hLIF-O4; L, hLIF-O5. B:
M, no antagonist; E, hLIF-O2; L, hLIF-O6; , hLIF-O4.
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example hGH (68) and also cytokines which involve het-
erodimerization in receptor activation such as interleukin 4
(69), IL-5 (64), and GM-CSF (70, 71). Similarly, in hLIF, abo-
lition of the gp130 binding site generates specific antagonists of
hLIF in the hLIF-responsive bioassay. The most active of these
antagonists, hLIF-O4, required 50–100-fold molar excess to
inhibit 50% activity of hLIF (Fig. 4). The requirement for an
excess of hLIF-O4 for significant inhibition is most likely a
result of the LIF-Rzgp130 complex having approximately a
100-fold greater affinity than the LIF-R for hLIF.
Generally, the antagonistic activity of the mutants impaired
in gp130 binding was negatively correlated with the residual
stimulation activity in the bioassay (Table I and Figs. 2 and 4).
However, the four mutants with essentially no bioactivity, yet
nearly identical LIF-R-Fc binding, also showed distinct differ-
ences in antagonism. For example, hLIF-O4 (Q25A, S28A, and
Q32A) was more effective than hLIF-O3 (Q25L, S28E, Q32A,
S36A; Fig. 4). These differences in the antagonist activity of the
hLIF mutants may be due to affinity differences for gp130,
undetectable in the binding assay. Alternatively, a more com-
plex interaction between the mutants and gp130 may explain
these antagonism differences.
The pleiotropic nature of LIF and the number of ligands that
utilize the LIF-R will probably mean that LIF-R-specific antag-
onists (the ability of these mutants to antagonize other LIF-R
binding ligands will be published elsewhere)3 will not be of use
therapeutically. However, the presence of soluble forms of
gp130 in human serum that are able in vitro to inhibit gp130-
dependent cell stimulation may indicate that general antago-
nists operate in vivo (72). Moreover, the antagonists will be of
use in dissecting the complex and overlapping actions of cyto-
kines that use LIF-R and gp130 as receptors.
Finally, the results presented here strongly reinforce a pat-
tern of receptor site usage among the long chain hematopoietin
cytokines (73). In this pattern, topologically conserved epitopes
on different cytokines are used to bind cytokine receptors. To
the initial paradigm of site I and II on hGH for GHR binding,
a third receptor binding location has been definitively added by
the mutational analysis of the known LIF structure presented
here (site III; Fig. 5). Site III has also been recently predicted to
bind a second molecule of gp130 on the modelled structure of
IL-6 (32). The known receptor binding sites for other long chain
cytokines are listed in Table II. The common usage of receptor
binding sites in this cytokine family suggests that other mem-
bers such as CT-1, oncostatin M, and IL-11 will also use topo-
logically similar epitopes.
The distribution of receptor binding epitopes in non-overlap-
ping regions of four helical bundle cytokines provides a spatial
explanation for multiple receptor engagement. However,
whether all complexes that involve heterotrimeric or even het-
erodimeric receptor engagement use a single ligand in the
activated receptor or also involve higher order associations of
ligands and receptors such as in the IL-6 complex (31, 32)
remains to be resolved. This issue represents an important
future goal for understanding the LIFzLIF-Rzgp130 signaling
complex
In summary, residues in hLIF that are important for binding
both the LIF-R and gp130 were identified in this study, the
disruption of the gp130 binding site resulted in the creation of
LIF-R antagonists.
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FIG. 5. Diagrammatic representation (Molscript; Ref. 80) of the hLIF structure2 depicting residues important for binding to its
receptors. The hLIF structure is very similar to the mLIF molecule apart from a shift in which the A-B loop crosses the D-helix. A, residues of
hLIF with a major impact on hLIF-R binding are displayed in red CPK and labeled. Residues with a moderate impact on binding are displayed
in magenta CPK. These residues are: Pro-51, Thr-150, Lys-158, and Val-175. N 5 amino terminus and C 5 carboxyl terminus. The putative site
I in hLIF would be centered around residue Val-175, site III is centered on residues Phe-156 and Lys-159. B, residues of hLIF that when mutated
collectively on either the A- or C-helix caused reduced binding to gp130. Residues on the A-helix are displayed in blue CPK, those on the C-helix
are displayed in yellow CPK. The residues in these two helices compose the equivalent of site II in hLIF. N 5 amino terminus and C 5 carboxyl
terminus.
TABLE II
Summary of receptor binding locations in the long chain
hematopoietin cytokines
Locations of receptor binding sites were assigned as noted under
“Discussion” and the references noted below.
Ligand Site I Site II Site III
hGH GHRa GHRb
LIF LIF-R? gp130 LIF-R
CNTF CNTF-Rc gp130d LIF-R?
IL-6 IL-6-Re gp130f gp130g
a Ref. 22.
b Ref. 25.
c Refs. 18 and 74.
d Ref. 74.
e Refs. 75–78.
f Ref. 63.
g Ref. 32.
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